Alcoholic Hepatitis: Steroids vs. Pentoxifylline
Alcoholic hepatitis (AH) remains a major cause of liver-related morbidity and mortality in the United States and is actually increasing in certain areas of Europe. Thus, there is a pressing need for new therapies/approaches. Major barriers for reducing morbidity, mortality, and costs of care include: lack of translational animal and human studies of new therapies for AH; limited trials of combination therapies in AH targeted at specific disease mechanisms (e.g., gut permeability, cytokines, oxidative stress); limited studies on non-invasive, non-mortality end points; few studies on mechanisms of steroid non-responsiveness; and inadequate prognostic indicators, to name only a few. In spite of these gaps, we have made major advances in understanding mechanisms for AH and appropriate therapies for AH. This article reviews mechanisms and rationale for use of steroids and pentoxifylline in AH and future directions in therapy.
KeywordsAlcoholic hepatitis Steroids Pentoxifylline Steroid resistance
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.• Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol. 2011;45(8):714–9. doi:10.1097/MCG.0b013e3181fdef1d. In-hospital mortality rate for AH remains high in the US, especially in those with infectious complications, hepatic encephalopathy, coagulopathy, and acute renal failure. Average length of stay was 6.5 ± 7.y days and average hospital charges were $37,769.PubMedCrossRefGoogle Scholar
- 6.Gobejishvili L, Crittenden N, McClain C. Controversies in hepatology: the experts analyze both sides. Thorofare: Slack; 2011. p. 3–10.Google Scholar
- 11.• Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60(2):255–60. doi:10.1136/gut.2010.224097. Analysis of individual data from five RCTs showed that corticosteroids significantly improve 28-day survival in patients with severe alcoholic hepatitis. The survival benefit is mainly observed inpatients classified as responders by the Lille model.PubMedCrossRefGoogle Scholar
- 12.Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis–a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Therapeut. 2008;27(12):1167–78. doi:10.1111/j.1365-2036.2008.03685.x.CrossRefGoogle Scholar
- 18.• di Mambro AJ, Parker R, McCune A, Gordon F, Dayan CM, Collins P. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis. Hepatology. 2011;53(4):1316–22. doi:10.1002/hep.24159. Clinical outcome of steroid therapy in an AH patient cohort correlated with in vitro steroid resistance and IL-2 blockade improved in vitro steroid sensitivity. Thus, intrinsic lack of steroid sensitivity may contribute to poor clinical response to steroids in severe AH and IL-2 receptor blocade may represent a possible intervention.PubMedCrossRefGoogle Scholar
- 19.• Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol. 2010;120(2–3):76–85. doi:10.1016/j.jsbmb.2010.02.018. Excellent review of mechanisms and resistance in glucocorticoid control of inflammation. New concepts in resistance including epigenetics are covered.PubMedCrossRefGoogle Scholar
- 25.Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009;137(2):541–8. doi:10.1053/j.gastro.2009.04.062.PubMedCrossRefGoogle Scholar
- 30.• Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci. 2012;57(6):1664–71. doi:10.1007/s10620-012-2097-4. This relatively small study (70 subjects) compared the efficacy of corticosteroids plus pentoxifylline with that of corticosteroids alone in improving survival of severe AH patients. Somewhat surprisingly, combination therapy showed no significant survival advantage, and results of larger trials are awaited.PubMedCrossRefGoogle Scholar
- 32.Gobejishvili L, Barve S, Joshi-Barve S, Uriarte S, Song Z, McClain C. Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NF-kappaB activity and TNF expression: relevance to alcoholic liver disease. Am J Gastrointest Liver Physiol. 2006;291(4):G681–8. doi:10.1152/ajpgi.00098.2006.CrossRefGoogle Scholar
- 33.Taguchi I, Oka K, Kitamura K, Sugiura M, Oku A, Matsumoto M. Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis. Inflamm Res Off J Eur Histamine Res Soc [et al]. 1999;48(7):380–5.Google Scholar
- 39.Gobejishvili L, Barve S, Joshi-Barve S, McClain C. Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2008;295(4):G718–24. doi:10.1152/ajpgi.90232.2008.PubMedCrossRefGoogle Scholar
- 40.Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev. 2009(4):CD007339. doi:10.1002/14651858.CD007339.pub2.
- 42.Tyagi P, Sharma P, Sharma BC, Puri AS, Kumar A, Sarin SK. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. Eur J Gastroenterol Hepatol. 2011;23(3):210–7. doi:10.1097/MEG.0b013e3283435d76.PubMedCrossRefGoogle Scholar